Where does First Tracks Biotherapeutics, Inc. Ordinary Shares's cash flow data come from?

Every line is extracted from First Tracks Biotherapeutics, Inc. Ordinary Shares's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26
Net income	-$50.48M-7.0%
Depreciation and amortization	$125K-14.4%
Stock-based compensation	$11.5M+48.5%
Change in accounts payable	$4.15M+215%
Net cash from operating activities	-$32.56M+27.7%
Capital expenditures	$17K-51.4%
Purchases of investments	$0-100%
Net cash from investing activities	$34.98M+136%
Net cash from financing activities	$7.85M+37.4%
Net increase (decrease) in cash	$10.27M+142%
Operating lease liabilities	$0+100%
Increase (Decrease) in Prepaid Expense and Other Assets	-$2.16M-587%
Operating lease right-of-use asset amortization	$0-100%
Proceeds From Sale And Maturity Of Available For Sale Securities	$35M-74.5%
Net Parent Investment Payment	-$7.85M-37.4%
Accrued payables for capital expenditures	$23K+109%
Increase Decrease In Operating Lease Liability	$0+100%
Unrealized Gain (Loss) on Investments	$8K-99.5%
Non Cash Transfer Of Assets And Liabilities	-$1.23M—
Free cash flow	-$32.58M+27.7%
Free cash flow	-$32.58M+27.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does First Tracks Biotherapeutics, Inc. Ordinary Shares's cash flow data come from?: Every line is extracted from First Tracks Biotherapeutics, Inc. Ordinary Shares's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.